Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research [Yahoo! Finance]
Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
avadel.com
Company Research
Source: Yahoo! Finance
acetylcholinesterase inhibitors, immunosuppressive drugs, and emerging therapies like monoclonal antibodies. Focus on improving patient life, reducing symptoms, and achieving long-term remission. New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG) treatment is set to experience significant growth in the coming years, propelled by a growing patient population, rising awareness, and the emergence of novel therapies. The global myasthenia gravis treatment market is forecasted to expand at a CAGR of 8.5% and thereby increase from a value of US$2.3Billion in 2023 to US$4.1Billion by the end of 2030. Myasthenia gravis is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It affects communication between nerves and muscles, leading to difficulties with swallowing, speaking, and daily activities. While there is n
Show less
Read more
Impact Snapshot
Event Time:
AVDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVDL alerts
High impacting Avadel Pharmaceuticals plc - Ordinary Share news events
Weekly update
A roundup of the hottest topics
AVDL
News
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8GlobeNewswire
- Avadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near Future [Yahoo! Finance]Yahoo! Finance
- Avadel Pharmaceuticals plc (NASDAQ: AVDL) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution [Seeking Alpha]Seeking Alpha
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference [Yahoo! Finance]Yahoo! Finance
AVDL
Earnings
- 11/8/23 - Miss
AVDL
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/15/24 - Form 8-A12B
- 4/15/24 - Form 8-K
- AVDL's page on the SEC website